209 results on '"Maral, Senem"'
Search Results
2. Single agent vemurafenib or rituximab-vemurafenib combination for the treatment of relapsed/refractory hairy cell leukemia, a multicenter experience
3. Analysis of factors associated with the development of myelofibrosis in polycythemia vera and essential thrombocythemia patients: a single-center experience
4. The outcome of COVID-19 in patients with hematological malignancy
5. Single Agent Vemurafenib or Rituximab-Vemurafenib Combination for the Treatment of Relapsed/Refractory Hairy Cell Leukemia, A Multicenter Experience
6. Relapsed refractory multiple myeloma with CNS involvement successfully treated with Elranatamab: first reported case
7. Primary Splenic Diffuse Large B Cell Lymphoma. Case Report and Literature Review
8. A Rare Entity in Chronic Myelocytic Leukemia: Coexistence of BCR ABL1 Translocation and JAK2 V617F Mutation. Case Report
9. Co-occurence of follicular lymphoma and Langerhans cell histiocytosis with primary parotid gland involvement: a case report
10. Rare aggressive natural killer cell leukemia presented with leukopenia and disseminated intravascular coagulation—a diagnostic challenge
11. The outcome of COVID-19 in patients with hematological malignancy
12. Acquired hemophilia with thrombosis in a cancer patient: an unusual presentation
13. Dimethyl Sulfoxide-Induced Tonic-Clonic Seizure and Cardiac Arrest During Infusion of Autologous Peripheral Blood Stem Cells
14. Does blood type have an effect on the course of COVID-19?
15. Single Centre Experience: Bening and Malign Hematological Patients with COVID-19
16. Castleman hastalığı: Türkiye’den çok merkezli bir olgu serisi
17. A rare case of pulmonary lymphomatoid granulomatosis complicated with venous thrombosis
18. Castleman Disease: A Multicenter Case Series from Turkey Castleman Hastalığı: Türkiye’den Çok Merkezli Bir Olgu Serisi
19. Clinical Characteristics and Outcomes of COVID-19 in Turkish Patients with Hematological Malignancies COVID-19 Geçiren Türk Hematolojik Malignite Hastalarının Klinik Özellikleri ve Sonuçları
20. Clinical Characteristics and Outcomes of COVID-19 in Turkish Patients with Hematological Malignancies
21. The impact of hematological parameters on survival for patients with COVID-19
22. Castleman Disease: A Multicenter Case Series from Turkey
23. Analysis of Demographic and Disease Characteristics of Patients with Chronic Myeloid Leukemia: A Single Centre Retrospective Analysis
24. An interim analysis of the Turkish Myeloma Registry among patients who have received up to two lines of therapy
25. Vitreous hemorrhage: A rare ophthalmic adverse effect due to imatinib treatment
26. An Interim Analysis of the Turkish Myeloma Registry Among the Patients Who Have Received up to Two Lines of Therapy
27. CASE REPORT OF MARGINAL ZONE LYMPHOMA DETECTED WHILE INVESTIGATING ETIOLOGY FOR HEMOSTASIS DISORDER
28. A CASE OF STAGE 1E DIFFUSE LARGE B-CELL LYMPHOMA PRESENTED WITH KNEE INVOLVEMENT
29. ANTI-CD52 TREATMENT EXPERIENCE IN A T-CELL PROLYMPHOCYTIC LEUKEMIA PATIENT:CASE REPORT
30. A RARE ASSOCIATION IN A CASE WITH HEREDITARY SPHEROCYTOSIS: SPECTRIN BETA (SPTB) AND JAK-2 MUTATION
31. A RARE CAUSE OF ANEMIA IN ADULTHOOD CONGENITAL DYSERYTHROPETIC ANEMIA
32. A RARE AND COMPLEX CAUSE OF IMPOTENCE POEMS SYNDROME
33. CASE REPORT: FOLLICULAR LYMPHOMA PRESENTED WITH CHYLOTHORAX
34. RECURRENT AUTOIMMUNE HEMOLYTIC ANEMIA AFTER MRNA COVID-19 VACCINE (PFIZER-BIONTECH)
35. T-ACUTE MYELOID LEUKEMIA CASE THOUGHT TO BE ASSOCIATED WITH RADIOIODINE (I¹³¹) TREATMENT
36. INAPPROPRIATE ADH SYNDROME OCCURING DURING B-ALL TREATMENT
37. IMPACT OF BONE MARROW FIBROSIS IN MYELOMA PATIENTS UNDERGONE AUTOLOGOUS STEM CELL TRANSPLANTATION
38. A RARE CASE: POSTTRANSPLANT NK/T CELL LYMPHOMA
39. DOES BLOOD TYPE HAVE AN EFFECT ON THE COURSE OF COVID-19?
40. THE IMPACT OF HEMATOLOGICAL PARAMETERS ON SURVIVAL FOR PATIENTS WITH COVID-19
41. A VERY RARE CAUSE OF DIARRHEA IN A CHEMOTHERAPY-INDUCED NEUTROPENIC PATIENT: PELLAGRA
42. P-125: An interim analysis of the Turkish Myeloma Registry among patients who have received up to two lines of therapy
43. Clinical Characteristics and Outcome of COVID-19 in Turkish Hematological Malignancy Patients
44. Clinical features and possible prognostic factors in patients with Marginal Zone Lymphoma: Retrospective analysis from two centers
45. A Real-life Turkish Experience of Venetoclax Treatment in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia
46. Development of plasma cell leukemia in a patient with chronic myeloid leukemia while on treatment with imatinib mesylate
47. Survival Outcomes of Hypomethylating Agents Maintenance Therapy In New Diagnosed AML Patients: Real Experience Data
48. REPLY FROM THE AUTHORS
49. Survival outcomes of hypomethylating agents maintenance therapy in new diagnosed AML patients: Real experience data.
50. Analysis of demographic and clinical characteristics of primary myelofibrosis and post-polycythemia vera/essential thrombocythemia myelofibrosis patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.